Aarkstore Market Research Report - Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation

Aarkstore Market Research Report - Frontier
Pharma: Parkinsons Disease - Identifying and
Commercializing First-in-Class Innovation
To buy this Report Visit
http://www.aarkstore.com

Discounted Market Research Reports available on Aarkstore.com
Offer valid till 28 th February, 2015
For more inquiries, contact at +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
To buy this Report Visit
http://www.aarkstore.com

Aarkstore Market Research Report - Frontier Pharma: Parkinsons
Disease - Identifying and Commercializing First-in-Class
Innovation
To buy this Report Visit
http://www.aarkstore.com

Summary
Large Degree of Innovation in Parkinsons Disease Pipeline
The Parkinsons disease (PD) pipeline currently has 302 products in active
development across all stages, but a stark contrast between the mechanisms of
action employed in the current market and the pipeline is evident. Where the
market relies on symptomatic treatments that target neuromodulatory
receptors, the pipeline shows a diverse range of neuroprotective therapies
targeting dysfunctional disease processes. This diversity is partially due to the
presence of 90 first-in-class products, which accounts for 37% of the overall
pipeline therapies that disclosed their target. In an industry, market and
development landscape that favors first-in-class over non-first-in-class
development in many ways, such as through faster approval or greater revenue,
this finding has strategic implications for a wide array of market participants,
both large and small. Despite their historically high attrition rate, first-in-class
therapies that reach the market have the potential to transform and improve the
PD treatment landscape.

Summary
Alignment of First-in-Class Molecular Target with Disease Processes
and Genetics
PD is a complex and multifaceted disease with a complex interplay between
different pathological processes. Enormous research efforts and significant
technological advances have furthered knowledge of the neuroanatomy of
the basal ganglia and of the fundamental processes underlying
neurodegeneration, helped by the ongoing identification of susceptibility
genes and causative genes in familial PD. Although the exact mechanisms
that initiate onset remain unclear, these insights have been translated into
the pool of novel therapeutic targets, which may potentially become diseasemodifying
therapies by aligning to the disease processes and some genetic
determinants of PD.

Summary
First-in-Class Products in Licensing and Co-development Deals
Strategic consolidation is relatively uncommon in the PD market.
Concerning first-in-class specifically, only nine first-in-class products that
are currently in development have been involved in licensing or codevelopment
deals since 2006. Despite the low sample size, it is clear that
the first-in-class PD products offer an attractive investment prospect as they
command much higher deal values and, on average, deals occur earlier in
development compared to non-first-in-class counterparts. Both trends were
substantiated by industry-wide data that showed that, particularly in Phase
I, first-in-class products would attract larger mean and median total deal
values. The data highlight that the first-in-class deals landscape is different
and indicates a greater chance of becoming much more lucrative than the
deals landscape for addition-to-class or advance-in-class therapies.

Scope
The report analyzes innovation in PD in the context of the overall pipeline and
current market landscape. It also analyzes the deals landscape surrounding
first-in-class products and pinpoints in-licensing opportunities.The report
includes -
- A brief introduction to PD, including symptoms, pathophysiology, and an
overview of pharmacotherapy and treatment algorithms
- Coverage of the changing molecular target landscape and particular points of
innovation in the pipeline
- A comprehensive review of the pipeline for first-in-class therapies, analyzed
by stage of development, molecule type and molecular target
- Identification and assessment of first-in-class molecular targets with a
particular focus on early-stage programs of which clinical utility has yet to be
evaluated, as well as literature reviews of novel molecular targets
- Industry-wide analysis of first-in-class deals compared to non-first-in-class
deals
- An assessment of the licensing and co-development deal landscape for PD
therapies and benchmarking of deals comparing first-in-class and non-first-inclass-products

Reasons To Buy
The report will enable business development and enable marketing executives
to strategize their product launches by allowing them to -
- Understand the focal shifts in molecular targets in the PD pipeline
- Understand the distribution of pipeline programs by phase of development,
molecule type and molecular target
- Access a scientific and clinical analysis of first-in-class developmental
programs for PD, benchmarked against non-first-in-class targets
- Assess the valuations of licensed and co-developed PD treatments
- Access a list of the first-in-class therapies potentially open to deal-making
opportunities
To know more about this report click here:
http://www.aarkstore.com/healthcare/89790/frontier-pharma-parkinsonsdisease-identifying-and-commercializing-first-in-class-innovation

Table of Contents
Frontier Pharma: Parkinsons Disease - Identifying and
Commercializing First-in-Class Innovation
Executive
Summary
The Case for
Innovation
Clinical and
Commercial
Landscape
Assessment of
Pipeline
Product
Innovation

Price Chart
Frontier Pharma: Parkinsons Disease - Identifying and
Commercializing First-in-Class Innovation
Product Price :
License Type
Price
PDF $ 6995
Site License $ 13990
Enterprise Wide Licence $ 20985
To View OR Purchase Report:
Click Here

Related Market Research Report
Traffic Safety Market in India 2015-2019
Blood Coagulation Analyzer – Product Analysis
Global Equine Healthcare Market 2015-2019
Epilepsy Market in the US 2015-2019
Global Ankylosing Spondylitis Market 2015-2019

Sickle-cell Anemia Therapeutics Market in the US 2015-2019
Global High-performance Thermoplastics Market 2015-2019
Global Anxiety Disorders Market 2015-2019
Global Breast Imaging Market 2015-2019
Global Cancer Biomarkers Market 2015-2019
Healthcare Market Research Reports

About Aarkstore Enterprise
• Aarkstore Enterprise provides Industry and Market Analysis and Research
Report with expertise and technology knowledge on business improvement and
market acquisition.
• Aarkstore achieved its debut pad in the year 2008 to explore, work on
assignments and cater worldwide clients and business giants with business
research on trends, markets and technologies. The latest set of applications
guarantees active analysis and Market Research understanding for budding
enterpriser and consultants to relate industry ground research.

Contact Us
Office
Office No. - 809, 8th Floor,
B-Wing, Mahaavir Icon,
Plot No.- 89 & 90, Sector-15,
CBD-Belapur, Navi Mumbai – 400614,
Maharashtra, India.
Telefax No: +91 22 4127 6660
24/7 Online Support: +91 9987295242
General Inquiries : +91 - 22 2756 4953
You Can Visit :
http://www.aarkstore.com
OR Mail us at :
contact@aarkstore.com
Blog :
http://www.aarkstore.com/blog/
Conference :
http://conference.aarkstore.com/
News :
http://www.aarkstore.com/news